Cargando…
Total escape of SARS-CoV-2 from dual monoclonal antibody therapy in an immunocompromised patient
Monoclonal antibodies (mAbs) directed against the spike of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are effective therapeutic options to combat infections in high-risk patients. Here, we report the adaptation of SARS-CoV-2 to the mAb cocktail REGN-COV in a kidney transplant patie...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10085998/ https://www.ncbi.nlm.nih.gov/pubmed/37037847 http://dx.doi.org/10.1038/s41467-023-37591-w |
_version_ | 1785022049570258944 |
---|---|
author | Jaki, Lena Weigang, Sebastian Kern, Lisa Kramme, Stefanie Wrobel, Antoni G. Grawitz, Andrea B. Nawrath, Philipp Martin, Stephen R. Dähne, Theo Beer, Julius Disch, Miriam Kolb, Philipp Gutbrod, Lisa Reuter, Sandra Warnatz, Klaus Schwemmle, Martin Gamblin, Steven J. Neumann-Haefelin, Elke Schnepf, Daniel Welte, Thomas Kochs, Georg Huzly, Daniela Panning, Marcus Fuchs, Jonas |
author_facet | Jaki, Lena Weigang, Sebastian Kern, Lisa Kramme, Stefanie Wrobel, Antoni G. Grawitz, Andrea B. Nawrath, Philipp Martin, Stephen R. Dähne, Theo Beer, Julius Disch, Miriam Kolb, Philipp Gutbrod, Lisa Reuter, Sandra Warnatz, Klaus Schwemmle, Martin Gamblin, Steven J. Neumann-Haefelin, Elke Schnepf, Daniel Welte, Thomas Kochs, Georg Huzly, Daniela Panning, Marcus Fuchs, Jonas |
author_sort | Jaki, Lena |
collection | PubMed |
description | Monoclonal antibodies (mAbs) directed against the spike of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are effective therapeutic options to combat infections in high-risk patients. Here, we report the adaptation of SARS-CoV-2 to the mAb cocktail REGN-COV in a kidney transplant patient with hypogammaglobulinemia. Following mAb treatment, the patient did not clear the infection. During viral persistence, SARS-CoV-2 acquired three novel spike mutations. Neutralization and mouse protection analyses demonstrate a complete viral escape from REGN-COV at the expense of ACE-2 binding. Final clearance of the virus occurred upon reduction of the immunosuppressive regimen and total IgG substitution. Serology suggests that the development of highly neutralizing IgM rather than IgG substitution aids clearance. Our findings emphasise that selection pressure by mAbs on SARS-CoV-2 can lead to development of escape variants in immunocompromised patients. Thus, modification of immunosuppressive therapy, if possible, might be preferable to control and clearance of the viral infection. |
format | Online Article Text |
id | pubmed-10085998 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-100859982023-04-12 Total escape of SARS-CoV-2 from dual monoclonal antibody therapy in an immunocompromised patient Jaki, Lena Weigang, Sebastian Kern, Lisa Kramme, Stefanie Wrobel, Antoni G. Grawitz, Andrea B. Nawrath, Philipp Martin, Stephen R. Dähne, Theo Beer, Julius Disch, Miriam Kolb, Philipp Gutbrod, Lisa Reuter, Sandra Warnatz, Klaus Schwemmle, Martin Gamblin, Steven J. Neumann-Haefelin, Elke Schnepf, Daniel Welte, Thomas Kochs, Georg Huzly, Daniela Panning, Marcus Fuchs, Jonas Nat Commun Article Monoclonal antibodies (mAbs) directed against the spike of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are effective therapeutic options to combat infections in high-risk patients. Here, we report the adaptation of SARS-CoV-2 to the mAb cocktail REGN-COV in a kidney transplant patient with hypogammaglobulinemia. Following mAb treatment, the patient did not clear the infection. During viral persistence, SARS-CoV-2 acquired three novel spike mutations. Neutralization and mouse protection analyses demonstrate a complete viral escape from REGN-COV at the expense of ACE-2 binding. Final clearance of the virus occurred upon reduction of the immunosuppressive regimen and total IgG substitution. Serology suggests that the development of highly neutralizing IgM rather than IgG substitution aids clearance. Our findings emphasise that selection pressure by mAbs on SARS-CoV-2 can lead to development of escape variants in immunocompromised patients. Thus, modification of immunosuppressive therapy, if possible, might be preferable to control and clearance of the viral infection. Nature Publishing Group UK 2023-04-10 /pmc/articles/PMC10085998/ /pubmed/37037847 http://dx.doi.org/10.1038/s41467-023-37591-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Jaki, Lena Weigang, Sebastian Kern, Lisa Kramme, Stefanie Wrobel, Antoni G. Grawitz, Andrea B. Nawrath, Philipp Martin, Stephen R. Dähne, Theo Beer, Julius Disch, Miriam Kolb, Philipp Gutbrod, Lisa Reuter, Sandra Warnatz, Klaus Schwemmle, Martin Gamblin, Steven J. Neumann-Haefelin, Elke Schnepf, Daniel Welte, Thomas Kochs, Georg Huzly, Daniela Panning, Marcus Fuchs, Jonas Total escape of SARS-CoV-2 from dual monoclonal antibody therapy in an immunocompromised patient |
title | Total escape of SARS-CoV-2 from dual monoclonal antibody therapy in an immunocompromised patient |
title_full | Total escape of SARS-CoV-2 from dual monoclonal antibody therapy in an immunocompromised patient |
title_fullStr | Total escape of SARS-CoV-2 from dual monoclonal antibody therapy in an immunocompromised patient |
title_full_unstemmed | Total escape of SARS-CoV-2 from dual monoclonal antibody therapy in an immunocompromised patient |
title_short | Total escape of SARS-CoV-2 from dual monoclonal antibody therapy in an immunocompromised patient |
title_sort | total escape of sars-cov-2 from dual monoclonal antibody therapy in an immunocompromised patient |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10085998/ https://www.ncbi.nlm.nih.gov/pubmed/37037847 http://dx.doi.org/10.1038/s41467-023-37591-w |
work_keys_str_mv | AT jakilena totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient AT weigangsebastian totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient AT kernlisa totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient AT krammestefanie totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient AT wrobelantonig totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient AT grawitzandreab totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient AT nawrathphilipp totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient AT martinstephenr totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient AT dahnetheo totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient AT beerjulius totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient AT dischmiriam totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient AT kolbphilipp totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient AT gutbrodlisa totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient AT reutersandra totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient AT warnatzklaus totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient AT schwemmlemartin totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient AT gamblinstevenj totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient AT neumannhaefelinelke totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient AT schnepfdaniel totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient AT weltethomas totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient AT kochsgeorg totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient AT huzlydaniela totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient AT panningmarcus totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient AT fuchsjonas totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient |